國立虎尾科技大學 |

Quantitative Decisions in Drug Development

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Quantitative Decisions in Drug Development/ by Christy Chuang-Stein, Simon Kirby.
作者:	Chuang-Stein, Christy.
其他作者:	Kirby, Simon.
面頁冊數:	XIX, 342 p. 86 illus., 21 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmacology/Toxicology. -
電子資源:	https://doi.org/10.1007/978-3-030-79731-7
ISBN:	9783030797317

Quantitative Decisions in Drug Development
Chuang-Stein, Christy.

Quantitative Decisions in Drug Development[electronic resource] /by Christy Chuang-Stein, Simon Kirby. - 2nd ed. 2021. - XIX, 342 p. 86 illus., 21 illus. in color.online resource. - Springer Series in Pharmaceutical Statistics,2366-8709. - Springer Series in Pharmaceutical Statistics,.

Chapter 1 - Clinical Testing of a New Drug -- Chapter 2 - A Frequentist Decision-making Framework -- Chapter 3 - Characteristics of a Diagnostic Test -- Chapter 4 - The Parallel Between Clinical Trials and Diagnostic Tests -- Chapter 5 - Incorporating Information from Completed Trials in Future Trial Planning -- Chapter 6 - Choosing Metrics Appropriate for Different Stages of Drug Development -- Chapter 7 - Designing Proof-of-Concept Trials with Desired Characteristics -- Chapter 8 - Designing Dose-response Studies with Desired Characteristics -- Chapter 9 - Designing Confirmatory Trials with Desired Characteristics -- Chapter 10 - Designing Phase 4 Trials -- Chapter 11 - Other Metrics That Have Been Proposed to Optimize Drug Development Decisions -- Chapter 12 - Discounting Prior Results to Account for Selection Bias -- Chapter 13 - Adaptive Designs -- Chapter 14 - Additional Topics.

This book focuses on important decision points and evidence needed for making decisions at these points during the development of a new drug. It takes a holistic approach towards drug development by incorporating explicitly knowledge learned from the earlier part of the development and available historical information into decisions at later stages. In addition, the book shares lessons learned from several select examples published in the literature since the publication of the first edition. The second edition reiterates the need for making evidence-based Go/No Go decisions in drug development discussed in the first edition. It substantially expands several topics that have seen great advances since the publication of the first edition. The most noticeable additions include three adaptive trials conducted in recent years that offer excellent learning opportunities, the use of historical data in the design and analysis of clinical trials, and extending decision criteria to the cases when the primary endpoint is binary. The examples used to illustrate the additional materials all come from real trials with some post-trial reflections offered by the authors. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. Prior knowledge includes information pertaining to historical controls. To assist decision making, the book discusses appropriate metrics and the formulation of go/no-go decisions for progressing a drug candidate to the next development stage. Using the concept of the positive predictive value in the field of diagnostics, the book leads readers to the assessment of the probability that an investigational product is effective given positive study outcomes. Lastly, the book points out common mistakes made by drug developers under the current drug-development paradigm. The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development process and the clinical trials conducted to support drug-marketing authorization. The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves.

ISBN: 9783030797317

Standard No.: 10.1007/978-3-030-79731-7doiSubjects--Topical Terms:

593882
Pharmacology/Toxicology.

LC Class. No.: QA276-280

Dewey Class. No.: 519.5

Quantitative Decisions in Drug Development
LDR:04868nam a22004095i 4500 001 1048139
003 DE-He213
005 20210903224620.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030797317 $9 978-3-030-79731-7
024 7 $a 10.1007/978-3-030-79731-7 $2 doi
035 $a 978-3-030-79731-7
050 4 $a QA276-280
072 7 $a PBT $2 bicssc
072 7 $a MAT029000 $2 bisacsh
072 7 $a PBT $2 thema
082 0 4 $a 519.5 $2 23
100 1 $a Chuang-Stein, Christy. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1142748
245 1 0 $a Quantitative Decisions in Drug Development $h [electronic resource] / $c by Christy Chuang-Stein, Simon Kirby.
250 $a 2nd ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a XIX, 342 p. 86 illus., 21 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Springer Series in Pharmaceutical Statistics, $x 2366-8709
505 0 $a Chapter 1 - Clinical Testing of a New Drug -- Chapter 2 - A Frequentist Decision-making Framework -- Chapter 3 - Characteristics of a Diagnostic Test -- Chapter 4 - The Parallel Between Clinical Trials and Diagnostic Tests -- Chapter 5 - Incorporating Information from Completed Trials in Future Trial Planning -- Chapter 6 - Choosing Metrics Appropriate for Different Stages of Drug Development -- Chapter 7 - Designing Proof-of-Concept Trials with Desired Characteristics -- Chapter 8 - Designing Dose-response Studies with Desired Characteristics -- Chapter 9 - Designing Confirmatory Trials with Desired Characteristics -- Chapter 10 - Designing Phase 4 Trials -- Chapter 11 - Other Metrics That Have Been Proposed to Optimize Drug Development Decisions -- Chapter 12 - Discounting Prior Results to Account for Selection Bias -- Chapter 13 - Adaptive Designs -- Chapter 14 - Additional Topics.
520 $a This book focuses on important decision points and evidence needed for making decisions at these points during the development of a new drug. It takes a holistic approach towards drug development by incorporating explicitly knowledge learned from the earlier part of the development and available historical information into decisions at later stages. In addition, the book shares lessons learned from several select examples published in the literature since the publication of the first edition. The second edition reiterates the need for making evidence-based Go/No Go decisions in drug development discussed in the first edition. It substantially expands several topics that have seen great advances since the publication of the first edition. The most noticeable additions include three adaptive trials conducted in recent years that offer excellent learning opportunities, the use of historical data in the design and analysis of clinical trials, and extending decision criteria to the cases when the primary endpoint is binary. The examples used to illustrate the additional materials all come from real trials with some post-trial reflections offered by the authors. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. Prior knowledge includes information pertaining to historical controls. To assist decision making, the book discusses appropriate metrics and the formulation of go/no-go decisions for progressing a drug candidate to the next development stage. Using the concept of the positive predictive value in the field of diagnostics, the book leads readers to the assessment of the probability that an investigational product is effective given positive study outcomes. Lastly, the book points out common mistakes made by drug developers under the current drug-development paradigm. The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development process and the clinical trials conducted to support drug-marketing authorization. The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves.
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Statistics, general. $3 671463
650 1 4 $a Statistical Theory and Methods. $3 671396
650 0 $a Pharmacology. $3 583819
650 0 $a Biostatistics. $3 783654
650 0 $a Statistics . $3 1253516
700 1 $a Kirby, Simon. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1142749
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030797300
776 0 8 $i Printed edition: $z 9783030797324
776 0 8 $i Printed edition: $z 9783030797331
830 0 $a Springer Series in Pharmaceutical Statistics, $x 2366-8695 $3 1267068
856 4 0 $u https://doi.org/10.1007/978-3-030-79731-7
912 $a ZDB-2-SMA
912 $a ZDB-2-SXMS
950 $a Mathematics and Statistics (SpringerNature-11649)
950 $a Mathematics and Statistics (R0) (SpringerNature-43713)